• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: ObsEva

Healthcare IPOs sputter as uncertainty, anxiety cloud–everything; what is an issuer and investor to do?

Steve Walker    March 2, 2017 March 2, 2017    No Comments on Healthcare IPOs sputter as uncertainty, anxiety cloud–everything; what is an issuer and investor to do?

Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »

Corporate, Government    AnaptysBio, Atlas Ventures, BioPharm Inside, Bloomberg, Bob Pisani, Braeburn Pharmaceuticals Inc., Bruce Booth, CNN, Dimitri Drone, Donald Trump, Federal Drug Adminstration, Initial Public Offering, IPO, Jim O’Neil, Jounce Therapeutics, Kathleen Smith, ObsEva, Peter Thiel, Renaissance Capital, Roger Perlmutter, Visterra

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
  • Three healthcare stocks shine while two fizzle to cap the first month of 2019’s investor lottery. Who’s a rational bet...
  • IPOs are back in business; well, unless and until there’s another government shutdown.
  • And now for something completely different in biotech: Lab-grown, “clean” meat. If Bill Gates and Warren Buffett like the idea...well?...
    • Elizabeth Holmes and Mark Zuckerberg: The rise and fall of the black turtleneck, hoodie and jeans. Op Ed
    • Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting,...
    • Biotech IPOs rock in 2018. More are storming into the queue.
    • Apitope moves Graves’ disease candidate toward Phase 2; a primer on autoimmune disease “for people in a hurry.”
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress